AbbVie Inc. — ABBV

CIK

0001551152

Tickers

ABBV

Exchange

NYSE

SIC

2834 Pharmaceutical Preparations

Status

ok

{"freshness":{"dto_schema_version":"meridian-agent-site/v1","status":"ok","status_reason":"ok","tearsheet_asof":"2026-07-16","tearsheet_schema_version":"financial-tearsheets/v1"},"identity":{"aliases":["ABBV"],"canonical_ticker":"ABBV","cik":"0001551152","exchange":"NYSE","industry_key":"healthcare","name":"AbbVie Inc.","sic":"2834","sic_description":"Pharmaceutical Preparations"},"shares":{"as_of":"2026-07-14","float_shares":1765382155,"free_float_factor":0.999202,"total_shares":1766792821}}

fundamentals[110]{fiscal_year,end,metric,value,unit,currency,filing_date,form,accession,concept}:
  2025,2025-12-31,revenue,61160000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
  2025,2025-12-31,cost_of_revenue,18204000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:CostOfGoodsAndServicesSold"
  2025,2025-12-31,selling_general_and_administrative,14010000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:SellingGeneralAndAdministrativeExpense"
  2025,2025-12-31,research_and_development,9096000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"
  2025,2025-12-31,operating_income,15075000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:OperatingIncomeLoss"
  2025,2025-12-31,interest_expense,2893000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:InterestExpense"
  2025,2025-12-31,pretax_income,6597000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"
  2025,2025-12-31,income_tax_expense,2364000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:IncomeTaxExpenseBenefit"
  2025,2025-12-31,net_income,4226000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:NetIncomeLoss"
  2025,2025-12-31,cash_and_equivalents,5229000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:CashAndCashEquivalentsAtCarryingValue"
  2025,2025-12-31,current_assets,29062000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:AssetsCurrent"
  2025,2025-12-31,total_assets,133960000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:Assets"
  2025,2025-12-31,current_liabilities,43289000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:LiabilitiesCurrent"
  2025,2025-12-31,total_debt,64997000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:DebtAndCapitalLeaseObligations"
  2025,2025-12-31,stockholders_equity,-3270000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:StockholdersEquity"
  2025,2025-12-31,operating_cash_flow,19030000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:NetCashProvidedByUsedInOperatingActivities"
  2025,2025-12-31,depreciation_and_amortization,762000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:Depreciation"
  2025,2025-12-31,stock_based_compensation,955000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:ShareBasedCompensation"
  2025,2025-12-31,capex,1214000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:PaymentsToAcquirePropertyPlantAndEquipment"
  2025,2025-12-31,free_cash_flow,17816000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"derived:operating_cash_flow-minus-capex"
  2025,2025-12-31,dividends_paid,11657000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:PaymentsOfDividends"
  2025,2025-12-31,share_repurchases,980000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:PaymentsForRepurchaseOfCommonStock"
  2025,2024-12-31,revenue,56334000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
  2025,2024-12-31,cost_of_revenue,16904000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:CostOfGoodsAndServicesSold"
  2025,2024-12-31,selling_general_and_administrative,14752000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:SellingGeneralAndAdministrativeExpense"
  2025,2024-12-31,research_and_development,12791000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"
  2025,2024-12-31,operating_income,9137000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:OperatingIncomeLoss"
  2025,2024-12-31,interest_expense,2808000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:InterestExpense"
  2025,2024-12-31,pretax_income,3716000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"
  2025,2024-12-31,income_tax_expense,-570000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:IncomeTaxExpenseBenefit"
  2025,2024-12-31,net_income,4278000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:NetIncomeLoss"
  2025,2024-12-31,cash_and_equivalents,5524000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:CashAndCashEquivalentsAtCarryingValue"
  2025,2024-12-31,current_assets,25582000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:AssetsCurrent"
  2025,2024-12-31,total_assets,135161000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:Assets"
  2025,2024-12-31,current_liabilities,38749000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:LiabilitiesCurrent"
  2025,2024-12-31,total_debt,67144000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:DebtAndCapitalLeaseObligations"
  2025,2024-12-31,stockholders_equity,3325000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:StockholdersEquity"
  2025,2024-12-31,operating_cash_flow,18806000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:NetCashProvidedByUsedInOperatingActivities"
  2025,2024-12-31,depreciation_and_amortization,764000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:Depreciation"
  2025,2024-12-31,stock_based_compensation,911000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:ShareBasedCompensation"
  2025,2024-12-31,capex,974000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:PaymentsToAcquirePropertyPlantAndEquipment"
  2025,2024-12-31,free_cash_flow,17832000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"derived:operating_cash_flow-minus-capex"
  2025,2024-12-31,dividends_paid,11025000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:PaymentsOfDividends"
  2025,2024-12-31,share_repurchases,1708000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:PaymentsForRepurchaseOfCommonStock"
  2025,2023-12-31,revenue,54318000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
  2025,2023-12-31,cost_of_revenue,20415000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:CostOfGoodsAndServicesSold"
  2025,2023-12-31,selling_general_and_administrative,12872000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:SellingGeneralAndAdministrativeExpense"
  2025,2023-12-31,research_and_development,7675000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"
  2025,2023-12-31,operating_income,12757000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:OperatingIncomeLoss"
  2025,2023-12-31,interest_expense,2224000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:InterestExpense"
  2025,2023-12-31,pretax_income,6250000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"
  2025,2023-12-31,income_tax_expense,1377000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:IncomeTaxExpenseBenefit"
  2025,2023-12-31,net_income,4863000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:NetIncomeLoss"
  2025,2023-12-31,cash_and_equivalents,12814000000.0,USD,USD,2025-02-14,10-K,0001551152-25-000020,"us-gaap:CashAndCashEquivalentsAtCarryingValue"
  2025,2023-12-31,current_assets,33002000000.0,USD,USD,2025-02-14,10-K,0001551152-25-000020,"us-gaap:AssetsCurrent"
  2025,2023-12-31,total_assets,134711000000.0,USD,USD,2025-02-14,10-K,0001551152-25-000020,"us-gaap:Assets"
  2025,2023-12-31,current_liabilities,37841000000.0,USD,USD,2025-02-14,10-K,0001551152-25-000020,"us-gaap:LiabilitiesCurrent"
  2025,2023-12-31,total_debt,59385000000.0,USD,USD,2025-02-14,10-K,0001551152-25-000020,"us-gaap:DebtAndCapitalLeaseObligations"
  2025,2023-12-31,stockholders_equity,10360000000.0,USD,USD,2025-02-14,10-K,0001551152-25-000020,"us-gaap:StockholdersEquity"
  2025,2023-12-31,operating_cash_flow,22839000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:NetCashProvidedByUsedInOperatingActivities"
  2025,2023-12-31,depreciation_and_amortization,752000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:Depreciation"
  2025,2023-12-31,stock_based_compensation,747000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:ShareBasedCompensation"
  2025,2023-12-31,capex,777000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:PaymentsToAcquirePropertyPlantAndEquipment"
  2025,2023-12-31,free_cash_flow,22062000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"derived:operating_cash_flow-minus-capex"
  2025,2023-12-31,dividends_paid,10539000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:PaymentsOfDividends"
  2025,2023-12-31,share_repurchases,1972000000.0,USD,USD,2026-02-20,10-K,0001551152-26-000008,"us-gaap:PaymentsForRepurchaseOfCommonStock"
  2024,2022-12-31,revenue,58054000000.0,USD,USD,2025-02-14,10-K,0001551152-25-000020,"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
  2024,2022-12-31,cost_of_revenue,17414000000.0,USD,USD,2025-02-14,10-K,0001551152-25-000020,"us-gaap:CostOfGoodsAndServicesSold"
  2024,2022-12-31,selling_general_and_administrative,15260000000.0,USD,USD,2025-02-14,10-K,0001551152-25-000020,"us-gaap:SellingGeneralAndAdministrativeExpense"
  2024,2022-12-31,research_and_development,6510000000.0,USD,USD,2025-02-14,10-K,0001551152-25-000020,"us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"
  2024,2022-12-31,operating_income,18117000000.0,USD,USD,2025-02-14,10-K,0001551152-25-000020,"us-gaap:OperatingIncomeLoss"
  2024,2022-12-31,interest_expense,2230000000.0,USD,USD,2025-02-14,10-K,0001551152-25-000020,"us-gaap:InterestExpense"
  2024,2022-12-31,pretax_income,13477000000.0,USD,USD,2025-02-14,10-K,0001551152-25-000020,"us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"
  2024,2022-12-31,income_tax_expense,1632000000.0,USD,USD,2025-02-14,10-K,0001551152-25-000020,"us-gaap:IncomeTaxExpenseBenefit"
  2024,2022-12-31,net_income,11836000000.0,USD,USD,2025-02-14,10-K,0001551152-25-000020,"us-gaap:NetIncomeLoss"
  2024,2022-12-31,cash_and_equivalents,9201000000.0,USD,USD,2024-02-20,10-K,0001551152-24-000011,"us-gaap:CashAndCashEquivalentsAtCarryingValue"
  2024,2022-12-31,current_assets,28463000000.0,USD,USD,2024-02-20,10-K,0001551152-24-000011,"us-gaap:AssetsCurrent"
  2024,2022-12-31,total_assets,138805000000.0,USD,USD,2024-02-20,10-K,0001551152-24-000011,"us-gaap:Assets"
  2024,2022-12-31,current_liabilities,29538000000.0,USD,USD,2024-02-20,10-K,0001551152-24-000011,"us-gaap:LiabilitiesCurrent"
  2024,2022-12-31,total_debt,63270000000.0,USD,USD,2024-02-20,10-K,0001551152-24-000011,"us-gaap:DebtAndCapitalLeaseObligations"
  2024,2022-12-31,stockholders_equity,17254000000.0,USD,USD,2024-02-20,10-K,0001551152-24-000011,"us-gaap:StockholdersEquity"
  2024,2022-12-31,operating_cash_flow,24943000000.0,USD,USD,2025-02-14,10-K,0001551152-25-000020,"us-gaap:NetCashProvidedByUsedInOperatingActivities"
  2024,2022-12-31,depreciation_and_amortization,778000000.0,USD,USD,2025-02-14,10-K,0001551152-25-000020,"us-gaap:Depreciation"
  2024,2022-12-31,stock_based_compensation,671000000.0,USD,USD,2025-02-14,10-K,0001551152-25-000020,"us-gaap:ShareBasedCompensation"
  2024,2022-12-31,capex,695000000.0,USD,USD,2025-02-14,10-K,0001551152-25-000020,"us-gaap:PaymentsToAcquirePropertyPlantAndEquipment"
  2024,2022-12-31,free_cash_flow,24248000000.0,USD,USD,2025-02-14,10-K,0001551152-25-000020,"derived:operating_cash_flow-minus-capex"
  2024,2022-12-31,dividends_paid,10043000000.0,USD,USD,2025-02-14,10-K,0001551152-25-000020,"us-gaap:PaymentsOfDividends"
  2024,2022-12-31,share_repurchases,1487000000.0,USD,USD,2025-02-14,10-K,0001551152-25-000020,"us-gaap:PaymentsForRepurchaseOfCommonStock"
  2023,2021-12-31,revenue,56197000000.0,USD,USD,2024-02-20,10-K,0001551152-24-000011,"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
  2023,2021-12-31,cost_of_revenue,17446000000.0,USD,USD,2024-02-20,10-K,0001551152-24-000011,"us-gaap:CostOfGoodsAndServicesSold"
  2023,2021-12-31,selling_general_and_administrative,12349000000.0,USD,USD,2024-02-20,10-K,0001551152-24-000011,"us-gaap:SellingGeneralAndAdministrativeExpense"
  2023,2021-12-31,research_and_development,6922000000.0,USD,USD,2024-02-20,10-K,0001551152-24-000011,"us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"
  2023,2021-12-31,operating_income,17924000000.0,USD,USD,2024-02-20,10-K,0001551152-24-000011,"us-gaap:OperatingIncomeLoss"
  2023,2021-12-31,interest_expense,2423000000.0,USD,USD,2024-02-20,10-K,0001551152-24-000011,"us-gaap:InterestExpense"
  2023,2021-12-31,pretax_income,12989000000.0,USD,USD,2024-02-20,10-K,0001551152-24-000011,"us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"
  2023,2021-12-31,income_tax_expense,1440000000.0,USD,USD,2024-02-20,10-K,0001551152-24-000011,"us-gaap:IncomeTaxExpenseBenefit"
  2023,2021-12-31,net_income,11542000000.0,USD,USD,2024-02-20,10-K,0001551152-24-000011,"us-gaap:NetIncomeLoss"
  2023,2021-12-31,cash_and_equivalents,9746000000.0,USD,USD,2023-02-17,10-K,0001551152-23-000011,"us-gaap:CashAndCashEquivalentsAtCarryingValue"
  2023,2021-12-31,current_assets,27928000000.0,USD,USD,2023-02-17,10-K,0001551152-23-000011,"us-gaap:AssetsCurrent"
  2023,2021-12-31,total_assets,146529000000.0,USD,USD,2023-02-17,10-K,0001551152-23-000011,"us-gaap:Assets"
  2023,2021-12-31,current_liabilities,35194000000.0,USD,USD,2023-02-17,10-K,0001551152-23-000011,"us-gaap:LiabilitiesCurrent"
  2023,2021-12-31,total_debt,76670000000.0,USD,USD,2023-02-17,10-K,0001551152-23-000011,"us-gaap:DebtAndCapitalLeaseObligations"
  2023,2021-12-31,stockholders_equity,15408000000.0,USD,USD,2023-02-17,10-K,0001551152-23-000011,"us-gaap:StockholdersEquity"
  2023,2021-12-31,operating_cash_flow,22777000000.0,USD,USD,2024-02-20,10-K,0001551152-24-000011,"us-gaap:NetCashProvidedByUsedInOperatingActivities"
  2023,2021-12-31,depreciation_and_amortization,803000000.0,USD,USD,2024-02-20,10-K,0001551152-24-000011,"us-gaap:Depreciation"
  2023,2021-12-31,stock_based_compensation,692000000.0,USD,USD,2024-02-20,10-K,0001551152-24-000011,"us-gaap:ShareBasedCompensation"
  2023,2021-12-31,capex,787000000.0,USD,USD,2024-02-20,10-K,0001551152-24-000011,"us-gaap:PaymentsToAcquirePropertyPlantAndEquipment"
  2023,2021-12-31,free_cash_flow,21990000000.0,USD,USD,2024-02-20,10-K,0001551152-24-000011,"derived:operating_cash_flow-minus-capex"
  2023,2021-12-31,dividends_paid,9261000000.0,USD,USD,2024-02-20,10-K,0001551152-24-000011,"us-gaap:PaymentsOfDividends"
  2023,2021-12-31,share_repurchases,934000000.0,USD,USD,2024-02-20,10-K,0001551152-24-000011,"us-gaap:PaymentsForRepurchaseOfCommonStock"

articles[3]{date,title,url,series,section,human_url}:
  2026-07-06,AbbVie Lowers Annual Profit Guidance Amid Billion-Dollar Acquisition,"https://agents.meridianindices.com/articles/2026-07-06/earnings-abbv-abbvie-lowers-annual-profit-guidance-amid-billion-dollar-acq/",Earnings,earnings,"https://marketbrain.meridianindices.com/marketbrain-2026-07-06-earnings-abbv-abbvie-lowers-annual-profit-guidance-amid-billion-dollar-acq.html"
  2026-06-22,AbbVie buys Apogee for $10.9 billion as immunology sales accelerate,"https://agents.meridianindices.com/articles/2026-06-22/earnings-abbv-abbvie-buys-apogee-for-10-9-billion-as-immunology-sales-acce/",Earnings,earnings,"https://marketbrain.meridianindices.com/marketbrain-2026-06-22-earnings-abbv-abbvie-buys-apogee-for-10-9-billion-as-immunology-sales-acce.html"
  2026-06-22,AbbVie to Buy Apogee Therapeutics in $10.9 Billion All-Cash Deal,"https://agents.meridianindices.com/articles/2026-06-22/deals-abbv-abbvie-to-buy-apogee-therapeutics-in-10-9-billion-all-cash-d/",Deals,deals,"https://marketbrain.meridianindices.com/marketbrain-2026-06-22-deals-abbv-abbvie-to-buy-apogee-therapeutics-in-10-9-billion-all-cash-d.html"